Remdesivir with Dexolve: fight against COVID-19

CycloLab, being involved in the fight, manufactures the critical excipient: sulfobutyl-ether-BCD (SBECD, Dexolve™) that enables Remdesivir to work. The unexpected and sudden outbreak along with the quick spread of the coronavirus-disease and rapid increase of the cases draw a sudden need for Dexolve.

The unexpected and sudden outbreak along with the quick spread of the coronavirus-disease and rapid increase of the cases draw a sudden need for Dexolve™ globally and CycloLab does its best in these troubled times.

CycloLab, being involved in the fight, manufactures the critical excipient: sulfobutyl-ether-BCD (SBECD, Dexolve™) that enables Remdesivir to work.

Combined with a wide range of further active pharmaceutical ingredients, it could improve their solubility or stability that could take effect not only for Remdesivir - a broad-acting antiviral with tremendous efficacy, but practically insoluble in water, preventing the preparation of an injectable formulation to treat patients - but almost any API. Accordingly, APIs get water-soluble and can exert their effects with increased effectiveness.

We encourage you to test the application of Dexolve by asking a 10g free-sample for evaluation and ask for the support of our scientists to answer the CD-related challenges.

It is our responsibility to secure healthy enviroment for both our ascendants and descendants.

If any of the above trigger further interest, I would be happy to to receive your revert to discuss further.